特发性肺纤维化患者是否接受抗纤维化治疗的生存期和肺功能病程:长期的结果INSIGHTS-IPF注册摩根富林明欧洲呼吸杂志乔欧元和J FD欧洲呼吸学会SP 1902279 10.1183/13993003.02279 -2019签证官56 2 A1 Behr188bet官网地址 Jurgen A1 Prasse, Antje A1 Wirtz,休伯特A1 Koschel,德克A1 Pittrow,大卫A1,马提亚A1 Klotsche, Jens A1安德烈亚斯,Stefan A1 Claussen,马丁A1高仪,Christian A1 Wilkens Henrike A1 Hagmeyer Lars A1 Skowasch Dirk A1 Meyer, Joachim F. A1 Kirschner, Joachim A1 Gläser, Sven A1 Kahn, Nicolas A1 Welte, Tobias A1 Neurohr, Claus A1 Schwaiblmair, Martin A1 Bahmer, Thomas A1 Oqueka, Tim A1 Frankenberger, Marion A1 KreuterMichael YR 2020 UL //www.qdcxjkg.com/content/56/2/1902279.abstract AB目的关于特发性肺纤维化(IPF)抗纤维化治疗的观察数据缺乏。我们的目的是评估现实生活条件下IPF患者接受和不接受抗纤维化治疗的病程。方法:我们分析了来自德国20个间质性肺病专家中心的连续入组IPF患者的非介入前瞻性队列研究数据。数据质量通过自动合理性检查、现场监控和源数据验证来保证。应用倾向评分来解释接受和未接受抗纤维化治疗的患者之间基线特征的已知差异。结果588例患者中，平均±sd年龄为69.8±9.1岁，男性占81.0%。自诊断以来的平均±sd病程为1.8±3.4年。基线时强迫肺活量(FVC)和扩散量(DLCO)的均值±sd分别为68.6±18.8%和37.8±18.5%。 During a mean±sd follow-up of 1.2±0.7 years, 194 (33.0%) patients died. The 1-year and 2-year survival rates were 87% versus 46% and 62% versus 21%, respectively, for patients with versus without antifibrotic therapy. The risk of death was 37% lower in patients with antifibrotic therapy (hazard ratio 0.63, 95% CI 0.45; 0.87; p=0.005). The results were robust (and remained statistically significant) on multivariable analysis. Overall decline of FVC and DLCO was slow and did not differ significantly between patients with or without antifibrotic therapy.Conclusions Survival was significantly higher in IPF patients with antifibrotic therapy, but the course of lung function parameters was similar in patients with and without antifibrotic therapy. This suggests that in clinical practice, premature mortality of IPF patients eventually occurs despite stable measurements for FVC and DLCO.Survival was significantly higher in antifibrotic-treated (AT) IPF patients, but the course of lung function parameters was similar in AT and non-AT patients, suggesting that functional stability alone may not safeguard against premature mortality in IPF https://bit.ly/2RDsrVY